RPRX
Royalty Pharma Plc
57.70$
-1.5%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +13.6% | -14.9% | +12.3% | +1.1% | +17.0% | +7.9% | -2.3% | +5.2% | -3.9% | +5.1% | |
| – | – | – | – | +308.7% | +649.7% | -77.4% | +96.2% | +99.7% | -38.0% | +30.6% | -99.5% | |
| – | – | +13.6% | -14.9% | +12.3% | +1.1% | +17.0% | +7.9% | -2.3% | +5.2% | -3.9% | +5.1% | |
| – | +262.9% | -7.5% | +29.5% | +233.1% | -78.9% | -68.3% | +661.1% | -11.5% | -70.6% | -96.2% | +22,500.0% | |
| – | -10.2% | -40.7% | +514.7% | -41.8% | +67.1% | +75.7% | +0.6% | +24.3% | +9.9% | -5.2% | +142.3% | |
| – | – | +37.5% | -39.4% | -34.6% | -287.9% | – | +63.0% | +124.8% | -55.3% | +12.6% | -15.7% | |
| – | – | -9.0% | +30.0% | +45.2% | +92.3% | -39.2% | -10.3% | -78.5% | +385.9% | -13.4% | +20.7% | |
| – | – | +6.5% | +3.5% | +13.2% | -4.1% | -41.5% | +5.8% | +13.1% | -0.4% | +20.5% | +36.4% | |
| – | – | +0.4% | +76.3% | +13.0% | +62.2% | -30.9% | -27.1% | -81.5% | +639.0% | -21.7% | -0.5% | |
| – | – | +10.6% | +176.9% | -20.1% | -19.4% | +228.3% | -33.5% | -75.4% | +201.9% | -16.5% | +17.2% | |
| – | – | -2.7% | +113.8% | +13.9% | +70.5% | -58.5% | -36.4% | -93.1% | +2,549.5% | -24.3% | -10.2% | |
| – | – | +24.0% | +51.9% | +12.8% | +50.4% | -31.7% | -24.0% | -70.4% | +345.4% | -17.5% | +5.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.